Who is buying/selling and why?, page-51

First 51 Last

Share
Profile

Follow
Superheat

144 Posts.

45

21/09/21

18:07

Post #: 56245091
Share

Originally posted by WoosterBrewster: ↑

The joys of lockdown extra curricular activities. Below is a snapshot comparison for anyone who wants to view just how undervalued LiveTiles really is right now. It’s absolutely mind boggling how undervalued it really is. I started putting this together last weekend but got side tracked. Since then, Big Tin Can has gone up another $100 mil market cap in a week (even Serko, a travel booking platform, yes travel! Has gone up $50 mil market cap in a week, even though their recurring revenue went majorly backwards).

I don’t like to necessarily look at percentage growth as the likes of Dubber, Serko and Nitro are building from a smaller base so obviously percentage growth will seem more pronounced! However, given LiveTiles has targeted break even and cost cutting, their ARR growth YoY is not too far off the pace and I anticipate they’ll look to turn on the “growth taps” once again once cash at bank starts to build and cash receipts continue to grow. (They’ve already started, $3.9m growth in ARR last quarter)

In my mind, I don’t see why we aren’t around the $650m - $800m. Even comparing to Dubber’s figures, there certainly seems like there is no reason why we shouldn’t hit $1bil market cap in the medium future. This certainly contradicts the suggestion from one poster that LVT could only reach $0.60 per share at best.

DYOR but if our peers are anything to compare against, we should be sitting at approx X10 multiple and a share price of $0.70 per share. How the hell you sit at 783.27m market cap at x69 multiple with declined recurring revenue of $13.5m is beyond me. It’s clear as day the share price is being manipulated. By who and why? I’m not sure.

Expand

Wooster I will cry with joy even if it hits 60c as I am sitting on a pile. The fact it held up pretty ok given the massive volatility in markets over the last few days has finally given me hope that we are turning the corner. Here is hoping your $1 comes good.

LVT Price at posting: 13.0¢ Sentiment: Buy Disclosure: Held
11 Upvote

3 Great analysis

Reply

Top Stories

HLX

Helix investor makes partial takeover bid, proposing board changes

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

There are more pages in this discussion • 56 more messages in this thread...

First 51 Last

Add LVT (ASX) to my watchlist

Who is buying/selling and why?, page-51

Top Stories

Helix investor makes partial takeover bid, proposing board changes

Lendlease sells off US east coast construction operations in latest global divestment push

The Calmer Co’s Anthony Noble reflects on record breaking FY24

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Featured News